Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments

Yuko Oku, an analyst from Morgan Stanley, maintained the Hold rating on Nautilus Biotechnolgy (NAUT – Research Report). The associated price target is $3.00.

Yuko Oku has given his Hold rating due to a combination of factors related to Nautilus Biotechnology’s current strategic and operational status. The company has delayed the commercial launch of its proteome analysis platform to late 2026, a year later than initially planned. This delay is attributed to necessary modifications in the platform’s assay configuration and surface chemistry, which are intended to reduce technical risks and improve the yield of affinity probes.
While the management’s efforts in cash management and progress towards a differentiated proteomics offering are positive, the upside potential remains limited until the platform’s launch. The company has also implemented a 16% reduction in force to extend its cash runway to 2027, reflecting a cautious approach to resource management amid the delayed timeline. Given these factors, Yuko Oku maintains a Hold rating, indicating a balanced view of the company’s prospects until further progress is demonstrated.